228 related articles for article (PubMed ID: 25199408)
1. Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation.
Goodrich AD
Expert Rev Hematol; 2014 Oct; 7(5):513-5. PubMed ID: 25199408
[TBL] [Abstract][Full Text] [Related]
2. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
5. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
Thomas X
Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib-induced neutrophilic panniculitis.
Zhang M; Hassan KM; Musiek A; Rosman IS
J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM
Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre P; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DiPersio J; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Rivera VM; Clackson T; Turner CD; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes T; Goldman JM; Shah NP; Kantarjian H;
N Engl J Med; 2013 Nov; 369(19):1783-96. PubMed ID: 24180494
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
15. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Petrungaro A; Gentile M; Mazzone C; Greco R; Uccello G; Recchia AG; De Stefano L; Bossio S; Palummo A; Morelli R; Musolino C; Morabito F; Vigna E
Chemotherapy; 2017; 62(6):353-356. PubMed ID: 28810255
[TBL] [Abstract][Full Text] [Related]
17. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
Shah NP
Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
[No Abstract] [Full Text] [Related]
20. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
